Sexton, BioSpherix collaborate to support cell & gene therapy needs

By The Science Advisory Board staff writers

June 12, 2020 -- Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish.

Sexton's off-the-shelf fill system, the Sexton Biotechnologies AF-500, will be combined with BioSpherix' Cytocentric isolator technology to allow for rapid process development and implementation of good manufacturing practice fill-finish.

With the AF-500, systems are ready to ship so developers can immediately begin process development of small volume fill and finish with the equipment they plan to use at clinical scale. Adding BioSpherix to the mix gives the technology the ability to operate within a fully closed environment along with the ability to control temperatures to limit risks during cryopreservation, the firms said.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.